Financial Personal
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCEĀ® and OFEVĀ® Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launches R&D expenditures increase by 14.2% to EUR 5.8 bn Boehringer Ingelheim today announced a strong
Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned. Research & Development (R&D) investments increased by 14.2% to EUR 5.8 billion. R&D investments were substantial, at 22.5% of net sales. Group net sales rose by 9.7%* to EUR 25.6 billion in 2023, driven by 10.3%* growth in Human Pharma and 6.9%* growth in Animal Health. Both businesses outperformed their markets. Read More
